Meeting
2020 ASCO Virtual Scientific Program
Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
Authors
Donna Molaie
UCLA Health, Los Angeles, CA
Donna Molaie , Albert Lai , Benjamin M. Ellingson , Thien Nguyen , Hye Hyun Bahng , Emese Filka , Stacey Green , Whitney B. Pope , Mei Leng , William H. Yong , Richard M. Green , Jonathan Polikoff , Liz Spier , Fabio Massaiti Iwamoto , Andrew B. Lassman , Timothy Francis Cloughesy , Phioanh Leia Nghiemphu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01149850
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2540)
DOI
10.1200/JCO.2020.38.15_suppl.2540
Abstract #
2540
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Phioanh Leia Nghiemphu
Poster
2013 ASCO Annual Meeting
BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation.
First Author: Jeffrey J. Raizer
Poster
2013 ASCO Annual Meeting
Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Αnocef phase II trial.
First Author: German Reyes-Botero
Poster
2023 ASCO Annual Meeting
Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.
First Author: David D. Tran